Experience

Kestrel Therapeutics
• United States
• Biotechnology
• 1 - 100 Employee
• Head Of Program Management

  • Jun 2022 - Present

Carmot Therapeutics, Inc.
• United States
• Biotechnology Research
• 1 - 100 Employee
• Head of Program Management

  • May 2021 - Jun 2022


Kura Oncology, Inc.

• United States
• Biotechnology Research
• 1 - 100 Employee

• Sr. Director Project Management - Oncology

  • Jun 2020 - Apr 2021

  • Accountable for highest priority program -Tipfarnib (HRAS biomarker directed oncology therapy) achieving FDA breakthrough designation. • Managed 8 clinical programs in Phase 1,2&3 for Tipifarnib and combination therapies • Oversaw Budget activities of $40M (2020), $300M (total), across Clinical, Pre-Clin, Pharmacology, CMC, Safety, Quality, Finance, and Regulatory Functions. • Optimized the PM function through standardization of project plans, risk management, goal setting, and implementation of cross functional roles and responsibilities. • Built and implemented the company Risk Assessment and Management Plan • Collaborated with external partners (Novartis, EORTC, Illumina, Qualtek, Strata, Q2) for biomarker directed combination therapies) Show less



Ipsen

• France
• Pharmaceutical Manufacturing
• 700 & Above Employee

• Director, Global Project Management

  • May 2019 - May 2020

  Oncology: • Managed Oncology Program in Phase 1 Clinical setting in a cross collaboration with MD Anderson. • Prioritized Program structure to save $9 Million from a 2020 $23 Million Budget. • Organized goals, key milestones and high level strategy/reporting for Clinical, Pre-clinical, Regulatory, Finance, API Development & supply, and DP Development & Clinical Manufacturing/AD functions. • Managed Efforts to support a Companion Diagnostic for our Phase 1 Oncology Program. Rare Disease: Fibrodysplasia ossificans progressiva (FOP), Multiple osteochondromas (MO), and Dry Eye • Coordinated Deliverables for Phase 2&3 Rare disease program, expanding into 11 countries. Including Regulatory filings, CMC support, and Clinical. • Created open communication and guidelines with newly aquired Clementia/Ipsen team members, integrating best practices for the Phase 2&3 Assets. Show less



Sarepta Therapeutics

• United States
• Biotechnology Research
• 700 & Above Employee

• Sr. CMC Project Manager

  • Jul 2018 - May 2019

  • CMC point of contact for PPMO platform technology development. • Collaborated with Manufacturing, Supply Chain, Quality Control, Quality Assurance, Non-clinical, Clinical and Regulatory Affairs to support all PPMO programs • Managed integrated strategies, project plans, critical milestones, and timelines and prepared regular project status reports for relevant asset teams. • Proactively identified and prioritized program risks and developed risk mitigation/contingency plans resulting in 4 month reductions of development to IND filings. • Facilitated team meetings and utilized operational mechanisms to drive cross-functional communication, decision making, and successful execution of program plans. Show less



Novartis Institutes for BioMedical Research (NIBR)

• United States
• Pharmaceutical Manufacturing
• 700 & Above Employee

• Project Leader

  • 2005 - May 2016

  • Led multiple discovery projects in metabolism, cardiovascular, and anti-infectives. • Managed internal and CRO synthesis of small molecule and protein drug candidates. • Orchestrated library screens and target validations. • Coordinated cross collaborations between chemistry, in-vitro and in-vivo biology, modeling, DMPK, formulations, and scale up teams. • Established IP and wrote patents for drugs. • Projects driven to successful clinical advancement • Led multiple discovery projects in metabolism, cardiovascular, and anti-infectives. • Managed internal and CRO synthesis of small molecule and protein drug candidates. • Orchestrated library screens and target validations. • Coordinated cross collaborations between chemistry, in-vitro and in-vivo biology, modeling, DMPK, formulations, and scale up teams. • Established IP and wrote patents for drugs. • Projects driven to successful clinical advancement


Procter & Gamble
• United States
• Manufacturing
• 700 & Above Employee
• Sr. Researcher

  • 1999 - 2004

Shionogi Bioresearch
• Scientist

  • 1997 - 1999